MedTrace Logo

Continuous Glucose Monitoring to Detect Postpartum Dysglycemia in Patients With Gestational Diabetes

NCT07034261 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-02-13

No results posted yet for this study

Summary

The aim of this study is to determine the ability of postpartum continuous glucose monitoring (CGM) for subjects with gestational diabetes (GDM) to predict dysglycemia on 4-12 week postpartum oral glucose tolerance test (OGTT).

Conditions

  • Gestational Diabetes

Interventions

DEVICE

Blinded Continuous Glucose Monitoring Device

Subjects will be asked to wear blinded continuous glucose monitoring device for 14 days.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Laura Dickens, MD · University of Chicago

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2026-06-30
Completion
2026-09-30
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07034261 on ClinicalTrials.gov